← Eichor
Study identifier: NCT06899126 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer  ·  Sponsor: Daiichi Sankyo

PhasePhase 3
Planned participants686
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.

This description comes directly from the study's public registry record.

Talk to the study team

Contact for Trial Information  ·  908-992-6400  ·  CTRinfo_us@daiichisankyo.com

Always discuss trial participation with your own doctor first.

Locations (237)

Alaska Oncology & Hematology, LLCAnchorage, Alaska, United StatesRecruiting
Orange Coast Memorial Medical Center Fountain ValleyFountain Valley, California, United StatesRecruiting
California Research InstituteLos Angeles, California, United StatesRecruiting
Los Angeles Cancer Network (LACN)Los Angeles, California, United StatesRecruiting
Providence Medical FoundationSanta Rosa, California, United StatesRecruiting
Bay Pines VA Healthcare SystemBay Pines, Florida, United StatesRecruiting
Lynn Cancer Institute CenterBoca Raton, Florida, United StatesRecruiting
Holy Cross HospitalFort Lauderdale, Florida, United StatesRecruiting
Mid-Florida Hematology & Oncology Centers, P.A.Orange City, Florida, United StatesRecruiting
BRCR Global PlantationPlantation, Florida, United StatesRecruiting
Cleveland Clinic Florida - WestonWeston, Florida, United StatesRecruiting
Piedmont Cancer Institute OneOncologyAtlanta, Georgia, United StatesRecruiting

+ 225 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06899126